Community-based patients who may benefit from COVID-19 TREATMENT

April 12, 2022

Does your patient have symptoms of COVID-19 that started in the last 5-7 days? [2]

E.g., fever, cough, change in sense of taste/smell, sore throat, stuffed nose, headache, tiredness, vomiting or diarrhea

Yes

Do they have risk factors for hospitalization from COVID-19? [3]

⚠️ The risk of severe COVID-19 depends on the number of factors ⚠️

Unvaccinated or partially vaccinated

Over 60 years old

Pregnant

Immunocompromised

Other health risks

This includes people who have specific health conditions (e.g., Common variable immunodeficiency [CVID]) or who take certain drugs that affect the immune system (e.g., chemotherapy).

E.g., BMI (Body Mass Index) ≥30 kg/m², diabetes, lung/heart/liver disease, renal disease (eGFR <60mL/min), sickle cell disease, cerebral palsy, and intellectual disability (e.g., Down syndrome).

Yes

They should be tested and considered for treatment. (As quickly as possible)

Outpatient treatments include:

- Paxlovid™
- Fluvoxamine
- Remdesivir
- Budesonide

Find the most recent Ontario COVID-19 Science Advisory Table’s COVID-19 Treatment Guidelines here:


Focused Covid Communication is: Andrea Chittle, MD, CCFP. Kelly Grindrod, BsCPharm, PharmD. Noah Ivers, MD, PhD, CCFP. Samira Jeimy, MD, PhD, FRCP. Tara Kiran, MD, MSc, CCFP, FCFP; Kate Miller, MD, CCFP. Menaka Pai, MSc, MD, FRCPC. Adrian Poon, BA. Sabina Vohra-Miller, MSc. Kristen Watt, BScPhm, RPh. Holly Witteman, PhD. Samantha Yammine, PhD. Reviewed by: Rosemary Killeen, BPharm, PGCert, RPh.

For questions about the reproduction, adaptation, translation, or other uses of this material, contact: phrcpd@uwaterloo.ca